Navigation Links
Par Pharmaceutical Begins Shipment of Generic Zyprexa® Zydis®
Date:10/24/2011

WOODCLIFF LAKE, N.J., Oct. 24, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 5mg, 10mg, 15mg, and 20mg strengths of olanzapine orally disintegrating tablets, the generic version of Lilly's Zyprexa® Zydis®. According to IMS Health data, annual sales in the U.S. of Zyprexa® Zydis® are approximately $360 million.

Important information about olanzapine ODT

Olanzapine is an atypical antipsychotic indicated as oral formulation for the:

  • Treatment of schizophrenia.
  • Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder.
  • Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks
  • Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder.

There are no labeled contraindications for olanzapine monotherapy. However, when using in combination with lithium or valproate, refer to the Contraindications section of the package inserts for those products.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Olanzapine orally disintegrating tablets are not approved for the treatment of patients with dementia-related psychosis. Refer to full prescribing information for complete boxed WARNING.

About Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press releases and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Future published a Half Cooked Research Report on Endoscopy Devices Market. ... million during the period 2016 to 2022 from USD 28.7 million ... ... as a swiftly growing market and expected to grow at a ... various regions.  The increasing growth in endoscopy procedures is influencing the ...
(Date:1/17/2017)... 17, 2016  Attorney Advertising -- Bronstein, Gewirtz & Grossman, ... Anthera Pharmaceuticals, Inc. ("Anthera" or the "Company") (NASDAQ: ... and assist the investigation by visiting the firm,s site: ... certain of its officers and/or directors have violated Sections 10(b) ... ...
(Date:1/17/2017)... 17, 2017  In a letter to President-elect ... Jenkins outlines AARP,s priorities for Americans age 50 ... access to affordable health care coverage, and lowering the ... Jenkins writes to President-elect Trump that "Our nearly 38 ... on you to protect their Medicare and Social Security ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Gym Source, America’s leading retailer of premium ... South Dixie Hwy in Miami, FL. , “We are elated to be opening this ... in-store concept is designed to give clients a seamless and motivating shopping experience.” , ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... improved supplement, Healthful-Flex. , The company, owned and operated by Ed Stroup, ... at a reasonable price with the highest level of customer service. Healthful Balance ...
(Date:1/17/2017)... ... ... Kevin Harrington (one of the original Sharks from mega-hit reality series Shark ... of Beauty and Personal Care. , Everyone makes New Year’s resolutions ... to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will be ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... 21st century approach to infusing high speed technology into the fabric of an ... to the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. ...
Breaking Medicine News(10 mins):